Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results

Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET

Vaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of Directors

Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

Vaxart Announces Results of Annual Meeting of Stockholders

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine